High plasma cardiac natriuretic peptides associated with enhanced cyclic guanosine monophosphate production in preascitic cirrhosis

Journal of Hepatology

Volumn 32, Issue 3, 2000, Pages 426-433

  Iwao, Tadashi ^a,b   Oho, Kazuhiko ^a   Nakano, Ryohichi ^a   Sakai, Teruhiro ^a   Sato, Masahiro ^a   Miyamoto, Yasunao ^a   Kumamoto, Masafumi ^a   Sakai, Kenji ^a   Sata, Michio ^a   Toyonaga, Atsushi ^a  

^a Div Gastroenterol Endoscopy   (Japan)

^b Iwao Hospital   (Japan)

Author keywords

Atrial natriuretic peptide; Brain natriuretic peptide; Cyclic guanosine monophosphate; Preascitic cirrhosis; Renal sodium handling

Indexed keywords

ALDOSTERONE; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CYCLIC GMP; NORADRENALIN; RENIN;

ADRENERGIC SYSTEM; ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; ASCITES; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; KIDNEY FUNCTION; LIVER CIRRHOSIS; MALE; NORADRENALIN BLOOD LEVEL; PLASMA; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RECUMBENCY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; SODIUM INTAKE; SODIUM METABOLISM; SODIUM URINE LEVEL;

EID: 0034009734     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(00)80393-1     Document Type: Article

References (47)

1. de Bold AJ. Atrial natriuretic factor: a hormone produced by the heart. Science. 230:1985;767-770.
2. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature. 332:1988;78-81.
3. Sudoh T, Minamino N, Kangawa K, Matsuo H. C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun. 168:1990;863-870.
4. Bie P, Wang BC, Leadley RJ Jr, Goetz KL. Hemodynamic and renal effects of low-dose infusions of atrial peptide in awake dogs. Am J Physiol. 254:((2 Pt 2)):1988;R161-R169.
5. Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, et al. Brain natriuretic peptide as a novel cardiac hormone in humans: evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest. 87:1991;1402-1412.
6. Furuya M, Yoshida M, Hayashi Y, Ohnuma N, Minamino N, Kangawa K, et al. C-type natriuretic peptide is a growth inhibitor of rat vascular smooth muscle cells. Biochem Biophys Res Commun. 177:1991;927-931.
7. Suga S, Nakao K, Hosoda K, Mukoyama M, Ogawa Y, Shirakami G, et al. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology. 130:1992;229-239.
8. Luk JK, Wong EF, Sun A, Wong NL. Cyclic guanosine monophosphate responses to atrial natriuretic factor, brain natriuretic peptide, but not C-type natriuretic peptide, and the characterization of their receptors in rat medullary thick ascending limb. Metabolism. 43:1994;1531-1535.
9. Levy M. Sodium retention and ascites formation in dogs with experimental portal circulation. Am J Physiol. 233:1977;F572-F585.
10. Epstein M, Pins D, Schneider N, Levinson R. Determinants of deranged sodium and water homeostasis in decompensated cirrhosis. J Lab Clin Med. 87:1976;822-839.
11. Vinel JP, Denoyel P, Viossat I, Cales P, Caucanas JP, Chabrier PE, et al. Atrial natriuretic peptide, plasma renin activity, plasma volume, systemic vascular resistance and cardiac output in patients with cirrhosis. J Gastroenterol Hepatol. 4:1989;529-535.
12. Colantonio D, Casale R, Pasqualetti P. Plasma levels of atrial natriuretic peptide in compensated and decompensated cirrhosis of the liver. Relationship with the renin-aldosterone system. Panminerva Med. 31:1989;166-170.
13. Salerno F, Badalamenti S, Moser P, Lorenzano E, Incerti P, Dioguardi N. Atrial natriuretic factor in cirrhotic patients with tense ascites. Effect of large-volume paracentesis. Gastroenterology. 98:1990;1063-1070.
14. Rector WG, Adair O, Hossack KF, Rainguet S. Atrial vole in cirrhosis: relationship to blood volume and plasma concentration of atrial natriuretic factor. Gastroenterology. 99:1990;766-770.
15. Kirstetter P, Moreau R, Vachiery F, Gadano A, Soupison T, Pilette C, et al. Plasma concentrations of cyclic 3′,5′-guanosine monophosphate in patients with cirrhosis: relationship with atrial natriuretic peptide and haemodynamics. J Gastroenterol Hepatol. 12:1997;233-236.
16. Salo J, Jimenez W, Kuhn M, Gines A, Gines P, Fernandez-Esparrach G, et al. Urinary excretion of urodilatin in patients with cirrhosis. Hepatology. 24:1996;1428-1432.
17. La Villa G, Romanelli RG, Casini Raggi V, Tosti-Guerra C, De Feo ML, Marra F, et al. Plasma levels of brain natriuretic peptide in patients with cirrhosis. Hepatology. 16:1992;156-161.
18. Trevisani F, Colantoni A, Sica G, D'Intino PE, De Notariis S, De Jaso R, et al. High plasma levels of atrial natriuretic peptide in preascitic cirrhosis: indirect evidence of reduced natriuretic effectiveness of the peptide. Hepatology. 22:1995;132-137.
19. Iwao T, Toyonaga A, Sato M, Oho K, Sakai T, Tayama C, et al. Effect of posture-induced blood volume expansion on systemic and regional hemodynamics in patients with cirrhosis. J Hepatol. 27:1997;484-491.
20. Bernardi M, Di Marco C, Trevisani F, De Collibus C, Fornalé L, Baraldini M, et al. The hemodynamic status of preascitic cirrhosis: an evaluation under steady-state conditions and after postural change. Hepatology. 16:1992;341-346.
21. Epstein M, Levinson R, Sancho J, Haber E, Re R. Characterization of the renin-aldosterone system in decompensated cirrhosis. Circ Res. 41:1977;818-829.
22. Nicholls KM, Shapiro MD, Van Putten VJ, Kluge R, Chung HM, Bichet DG, et al. Elevated plasma norepinephrine concentration in decompensated cirrhosis. Circ Res. 56:1985;457-461.
23. Pugh RNH, Murray-Lyron M, Dawson JL, Pietroni MC, Williams R. Transsection of oesophagus for bleeding oesophageal varices. Br J Surg. 60:1973;646-649.
24. Hama N, Nakao K, Mukoyama M, Suga S, Ogawa Y, Kawabata Y, et al. Fundamental and clinical evaluation of 'Shionoria ANP,' human atrial natriuretic peptide IRMA kit. Clin Report. 25:1991;455-462.
25. Yasue H, Yoshimura M, Jougasaki M, Ito H, Suga S, Ogawa Y, et al. Plasma levels of brain natriuretic peptide in normal subjects and patients with chronic heart failure: measurements by immunoradiometric assay (IRMA). Horm Clin. 41:1993;397-403.
26. Menard J, Guyenne TT, Corvol P, Pau B, Simon D, Roncucci R. Direct radioimmunoassay of active renin in human plasma. J Hypertens. 3:(suppl 3):1985;S275-S278.
27. Hubl W, Buchner M, Stahl F, Rohde W. Radioimmunoassay for aldosterone in plasma without chromatography. Endokrinologie. 66:1975;292-300.
28. Yamatodani A, Wada H. Automated analysis for plasma epinephrine by liquid chromatography, including a sample cleanup procedure. Clin Chem. 27:1981;1983-1987.
29. Wood PJ, Marks V. Direct measurement of cGMP in blood plasma and urine by radioimmunoassay. Ann Clin Biochem. 15:1978;25-30.
30. Maack T, Suzuki M, Almeida FA, Nussenzveig D, Scarborough RM, McEnroe GA, et al. Physiological role of silent receptors of atrial natriuretic factor. Science. 238:1987;675-678.
31. Ginès P, Jimènez W, Arroyo V, Navasa M, López C, Titó L, et al. Atrial natriuretic factor in cirrhosis with ascites: plasma levels, cardiac release and splanchnic extraction. Hepatology. 8:1988;636-642.
32. Poulos JE, Gower WR, Fontanet HL, Kalmus GW, Vesely DL. Cirrhosis with ascites: increased atrial natriuretic peptide messenger RNA expression in rat ventricle. Gastroenterology. 108:1995;1496-1503.
33. Goetz KL. Physiology and pathophysiology of atrial peptides. Am J Physiol. 254:1988;E1-E15.
34. Wong F, Liu P, Alliddina Y, Blendis LM. Pattern of sodium handling and its consequences in patients with preascitic cirrhosis. Gastroenterology. 108:1995;1820-1827.
35. Rector WG, Hossack KF. Pathogenesis of sodium retention complicating cirrhosis: is there room for diminished "effective" arterial blood volume? Gastroenterology. 95:1988;1658-1663.
36. Yasue H, Yoshimura M, Shimada H, Kikuta T, Kugiyama K, Jougasaki M, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 90:1994;195-203.
37. Wilkins MA, Su XL, Palayew MD, Yamashiro Y, Rolli P, McKenzie JK, et al. The effects of posture change and continuous positive airway pressure on cardiac natriuretic peptides in congestive heart failure. Chest. 107:1995;909-915.
38. Chinkers M, Garbers DL. Signal transduction by guanylyl cyclases. Annu Rev Biochem. 60:1991;553-575.
39. Lang CC, Choy AMJ, Struthers AD. Atrial and brain natriuretic peptides: a dual natriuretic peptide system potentially involved in circulatory homeostasis. Clin Sci. 83:1992;519-527.
40. Moncada S, Palmer RJM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 43:1991;109-142.
41. Vorderwinkler KP, Jakob G, Mair J, Judmaier G, Puschendorf B. Uncoupling of atrial natriuretic peptide and cyclic 3′,5′-guanosine monophosphate production in patients with liver cirrhosis. Clin Invest. 72:1994;138.
42. 2 in liver cirrhosis: relation to blood volume and changes in blood volume after furosemide. Eur J Clin Invest. 20:1990;632-641.
43. Gerbes AL, Kollenda MC, Vollmar AM, Reichen J, Vakil N, Scarborough RM. Altered density of glomerular binding sites for atrial natriuretic factor in bile duct-ligated rats with ascites. Hepatology. 13:1991;562-566.
44. Ni X, Cheng Y, Cao L, Gardner DG, Humphreys MH. Mechanisms contributing to renal resistance to atrial natriuretic peptide in rats with common bile-duct ligation. J Am Soc Nephrol. 7:1996;2110-2118.
45. Holmes SJ, Espiner EA, Richards AM, Yandle TG, Frampton C. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab. 76:1993;91-96.
46. Cargill RI, Struthers AD, Lipworth BJ. Comparative effects of atrial natriuretic peptide and brain natriuretic peptide on the aldosterone and pressor responses to angiotensin II in man. Clin Sci. 88:1995;81-86.
47. La Villa G, Riccardi D, Lazzeri C, Casini Raggi V, Dello Sbarba A, Tosti Guerra C, et al. Blunted natriuretic response to lowdose brain natriuretic peptide infusion in nonazotemic cirrhotic patients with ascites and avid sodium retention. Hepatology. 22:1995;1745-1750.